Confluence, now publicly traded Aclaris Therapeutics, is a clinical stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options
Aclaris has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation
Highlights
Confluence raised multiple rounds of venture capital financing and established a profitable business unit
Confluence was acquired by Aclaris Therapeutics (Nasdaq: ACRS), providing returns to investors
As Aclaris Therapeutics, the Confluence drug candidates continue to advance in clinical trials
BioGenerator was deeply committed to working with the founders to build a successful company. Without the ongoing support of BioGenerator, the Confluence story would never have happened.
Joseph Monahan Co-Founder and CSO, Confluence (NASDAQ:ACRS)
BioGenerator Contributions
BioGenerator was Confluence's first investor and continued as the lead investor through multiple early rounds of financing, then continued to invest up until the exit
Confluence was the first client of the BioGenerator Labs and leveraged BioGenerator's facility from inception through acquisition
BioGenerator was the only investor in Confluence's CRO subsidiary, Confluence Discovery Technologies
Charlie Bolten, Senior Managing Director of BioGenerator Ventures, served on the company's board from first financing through successful exit
